How Often Should You Receive MRD Testing While In Remission?
While remission (or state of complete response) can be an exciting time for myeloma patients, there might be a level of stress surrounding the monitoring of the disease for the inevitable relapse. And while MRD testing can help provide insight on the disease's activity within the body, excessive MRD testing might become costly or negatively affect your quality of life. Here to help share insight on this complicated topic is multiple myeloma specialist Dr. Joshua Richter from Mount Sinai Hospital in NYC. Be prepared to learn with us and come with questions!
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Joshua Richter, MD
Joshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology. He is the director of Multiple Myeloma at the Blavatnik Family- Chelsea Medical Center at Mount Sinai. Dr. Richter treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, plasma cell leukemia, and Waldenstrom’s Macroglobulinemia. Dr. Richter has extensive experience with clinical trials focused on novel therapies, including antibody therapy and immunotherapy for a precision medicine approach. He has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally. He has been published in journals such as the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology.